Researchers have begun testing a new treatment for progressive multiple sclerosis (MS) called pegsebrenatide, which is currently in a Phase 2 clinical trial. This trial, known as the TAG-MS study, involves about 120 participants who will receive either pegsebrenatide or a placebo once a week for 96 weeks. The study aims to measure changes in brain health using MRI scans and assess various neurological functions, which could lead to improved outcomes for people living with MS.

This trial matters for anyone concerned about aging and neurological health. Progressive MS can lead to significant disability, affecting mobility and quality of life. If pegsebrenatide proves effective, it could help slow the progression of this disease, potentially preserving cognitive and physical abilities for a longer time. The study is particularly relevant for younger individuals with MS, as earlier research suggests they may experience greater benefits from this treatment.

Currently, the evidence for pegsebrenatide is based on preclinical studies and previous trials in other conditions like Parkinson’s disease. While these initial results are promising, they are not yet confirmed in humans with MS. The ongoing study will provide crucial data on its effectiveness and safety in this specific population. As the trial progresses, it will be important to stay informed about the outcomes, especially for those who may be affected by progressive MS or are interested in treatments that could enhance brain health as they age.

Source: longevity.technology